Compare GE Vernova Inc (GEV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Smith & Nephew plc — how do they compare? GE Vernova Inc trades at $1,005.78 (market cap $266.16B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: GE Vernova Inc is far larger — about 24× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Smith & Nephew plc for 120 Days on average.
| GEV | SNN | |
|---|---|---|
Market Cap | $266.16B | $11.10B |
Volume | 2,324,165 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $1.17K | $37.17 |
52-Week Low | $547.96 | $26.42 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | $255.83B | $14.13B |
Dividend Yield | 0.2% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $986.62, down 1.05% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical momentum with support at $973 and resistance at $1,026. Recent Q1 2026 earnings beat expectations with EPS of $17.44 versus $1.95 expected, while Q2 2026 missed estimates. The company secured the first US construction permit for its BWRX-300 small modular reactor, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with projected revenue growth to $41.4B in 2026 and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and EV/EBITDA of 85.22, plus execution challenges in scaling nuclear projects. The stock offers exposure to AI infrastructure growth but requires monitoring of margin expansion and backlog conversion.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
